That's because mis-regulation of Myc proteins is a hallmark of cancer and N-Myc plays a key role in childhood brain cancers. "Because Aurora-A stabilizes N-Myc against degradation, inhibiting the ...

Scientists have developed a peptide that holds promise in controlling the activity of the MYC protein, a key contributor to exacerbating 75 percent of human cancer cases. According to researchers ...

What additional lessons can be learned? Is MYC stability altered at specific subcellular locales, or when in partnership with certain DNA, RNA or protein molecules, or as a mechanism to regulate ...

Known as Myc, it was one of the first so-called oncogenes ever discovered. It’s mutated or dysregulated in perhaps 70% of all cancers. The challenge is that the protein it creates is ...

That's because mis-regulation of Myc proteins is a hallmark of cancer and N-Myc plays a key role in childhood brain cancers. "Because Aurora-A stabilizes N-Myc against degradation, inhibiting the ...

Yang’s team instead turned their focus towards an ‘undruggable’ oncogene, known as MYC — which produces a protein that can cause cells to become cancerous. MYC was identified in 1983 by a ...

In addition to being an oncogene, MYC is also one of the four Yamanaka factors, which are four protein transcription factors that can revert highly specified cells (such as a skin cell ...

A new approach to targeting a protein involved in cell division, which can misfunction in cancer, has revealed new insights into how it functions. The protein, called Aurora-A, is one of a group of ...

MRT-2359. That program is MRT-2359, an oral MGD designed to target translation termination factor protein GSPT1 for the treatment of MYC oncogene-driven tumors, including metastatic non-small cell ...